BridgeBio Pharma, Inc. (BBIO)
BBIONASDAQ-GSBiotechnology: Pharmaceutical Preparations
$77.93
+3.64 (+4.90%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $15.18bn
- P/E
- –
- EPS, last 4 quarters
- $-3.04
- Dividend yield
- –
- Day range
- –
- 52-week range
- $60.55 to $93.42
- Average volume
- 2.79m
- Previous close
- $74.29
Analysts
18 coveringBuy17 buy, 1 hold, 0 sell
Targets a year out average $109.69, +40.8% from here
Earnings
next estimate $-0.5900Next report
Dec 2025
-33.3%
Mar 2026
-20.0%
Jun 2026
-21.9%
Sep 2026
+30.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $154.18m | $194.51m | $243.68m | $353.17m |
| Gross profit | $146.07m | $184.58m | $228.63m | $332.72m |
| Operating income | -$139.56m | -$105.96m | -$107.08m | -$11.64m |
| Net income | -$265.47m | -$182.33m | -$158.65m | -$31.99m |
Last four quarters: revenue $945.54m, margin -67.5%, free cash flow -$369.81m
News
8 latest- Should You Invest $1,000 in BridgeBio Pharma Right Now?The Motley Fool · Nov 2, 2026
- BridgeBio (BBIO) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 30, 2026
- BridgeBio Pharma, Inc. Reports Third Quarter 2026 Financial Results and Corporate UpdatesFintel · Oct 29, 2026
- What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings CallMarketBeat · Oct 29, 2026
- BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · Oct 29, 2026
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesZacks · Oct 29, 2026
- Biotech Stocks Facing FDA Decision In November 2026 RTTNews · Oct 29, 2026
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsZacks · Oct 21, 2026
The company
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- bridgebio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.